Oxford Nanopore Technologies plc

Equities

ONT

GB00BP6S8Z30

Advanced Medical Equipment & Technology

Market Closed - London S.E. Other stock markets 16:35:25 14/04/2026 BST			5-day change	1st Jan Change
112.90 ^GBX	+7.12%		-5.84%	-12.07%

04-09	WINNERS & LOSERS: ME Group rises on Asda deal; BP tracks oil higher	AN
03-30	WINNERS & LOSERS: Miners climb; Close Brothers down before FCA verdict	AN

Oxford Nanopore chair Tatton-Brown buys GBP100,000 in shares

Published on 03/03/2026 at 12:14 pm GMT

Alliance News

OXFORD NANOPORE TECHNOLOGIES PLC

+7.12%

Oxford Nanopore Technologies PLC - Oxford, England-based specialist in DNA and RNA sequencing technologies - Chair Duncan Tatton-Brown buys 87,000 ordinary shares at GBP1.1550 each on Monday, the same day the company reports a narrowing pretax loss and double-digit revenue growth in its 2025 results. The transaction is worth GBP100,485 in total.

Current stock price: 114.80 pence

12-month change: up 9.2%

By Eva Castanedo, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Oxford Nanopore Technologies plc

04-09	WINNERS & LOSERS: ME Group rises on Asda deal; BP tracks oil higher	AN
03-30	WINNERS & LOSERS: Miners climb; Close Brothers down before FCA verdict	AN
03-25	Morgan Stanley raises BP and Croda, cuts Shell	AN
03-24	Goldman Sachs cuts National Grid and SSE	AN
03-17	Oxford Nanopore & A.D.A.M. Innovations partner to advance genomic medicine in Japan	RE
03-17	Oxford Nanopore Technologies And A.D.A.M. Innovations Announce International Collaboration To Accelerate Advanced Genomic Medicine In Japan	CI
03-11	Oxford Nanopore Technologies plc Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 03:30 PM
03-10	Oxford Nanopore Technologies plc Announces Termination of Dr Gurdial Singh Sanghera as Director, Effective March 2, 2026	CI
03-03	Oxford Nanopore chair Tatton-Brown buys GBP100,000 in shares	AN
03-02	Oxford Nanopore Technologies plc Provides Earnings Guidance for the Year 2026	CI
03-02	Oxford Nanopore Technologies plc, 2025 Earnings Call, Mar 02, 2026
03-02	Oxford Nanopore shares fall as revenue grows in 2025	AN
03-02	FTSE 100 down, UK mortgage approvals decline	AN
03-02	Price targets raised for BP and Shell	AN
03-02	Oxford Nanopore Technologies plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Chart Oxford Nanopore Technologies plc

Duration

Period

ONT: Dynamic Chart

Company Profile

Oxford Nanopore Technologies plc is engaged in the generation of molecular sensing technology based on nanopores. The Company has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Companyâ€™s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.

Employees

1,335

Sector

Advanced Medical Equipment & Technology

Calendar

08-19 - Earnings release - Q2 2026

More about the company